Mehrnaz N Jamali, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
- Since medical school
- 33 years
- Texas Tech University Health Science Center School of Medicine, 1993
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Jamali’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A53933 · Current
Licensed to practise in California · since 1995 · expires 2026-10-31 · University of Texas Medical School at Houston.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$29,147
Medicare paid this office $29,147 for 123 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $12,910 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $9,187 | $156 |
| Hospital discharge day management, 30 minutes or less | 70 | $5,286 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,059 | $71 |
Who their Medicare patients are
123 Original Medicare patients in 2024. Average age 79 · 85 and older 32% · Women 56% · Also on Medicaid 34% · Health risk score 2.54. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Heart failure 75% · Coronary heart disease 72% · Atrial fibrillation 67% · Chronic kidney disease 56% · Diabetes 48% · COPD 28% · Cancer 24% · Depression 24% · Stroke 20% · Dementia 19%.
The office billed $125,809, Medicare allowed $36,754 and paid $29,147; for 273 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 123 | 273 | 79 | 2.54 | $125,809 | $29,147 |
| 2023 | 310 | 863 | 76 | 2.25 | $522,747 | $71,650 |
| 2022 | 455 | 1,552 | 74 | 2.14 | $801,564 | $103,345 |
| 2021 | 345 | 1,076 | 75 | 2.53 | $689,347 | $93,696 |
| 2020 | 277 | 854 | 75 | 2.96 | $681,151 | $85,541 |
| 2019 | 208 | 495 | 77 | 2.89 | $357,147 | $52,023 |
| 2018 | 223 | 600 | 77 | 2.81 | $232,192 | $58,883 |
| 2017 | 124 | 291 | 82 | 1.45 | $71,126 | $26,803 |
| 2016 | 91 | 143 | 85 | 1.45 | $36,533 | $10,332 |
| 2014 | 73 | 269 | 76 | 1.03 | $37,388 | $20,397 |
| 2013 | 93 | 417 | 74 | 0.93 | $58,066 | $32,354 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $35,648 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 100 | $14,470 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 66 | $8,293 | $70 |
| Hospital discharge day management, 30 minutes or less | 98 | $7,128 | $71 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 58 | $1,860 | $16 |
| New patient visit (15+ min) | 34 | $1,525 | $45 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | 19 | $1,181 | $56 |
| Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | 19 | $1,054 | $41 |
2022: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 180 | $41,006 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 97 | $13,384 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $11,759 | $170 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | 143 | $7,292 | $31 |
| Hospital discharge day management, 30 minutes or less | 98 | $6,521 | $65 |
| New patient visit (15+ min) | 118 | $6,442 | $55 |
| Initial hospital observation care per day, typically 70 minutes | 37 | $5,704 | $154 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 90 | $3,825 | $20 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,431 | $95 |
| Follow-up observation care per day, typically 35 minutes | 15 | $1,264 | $84 |
| Hospital observation care on day of discharge | 18 | $1,098 | $61 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 29 | $1,059 | $35 |
| Advance care planning, first 30 minutes | 14 | $1,037 | $69 |
| Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | 18 | $907 | $41 |
2021: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 174 | $42,314 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $9,589 | $178 |
| Initial hospital observation care per day, typically 70 minutes | 50 | $8,270 | $162 |
| Hospital discharge day management, more than 30 minutes | 75 | $7,343 | $97 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | 41 | $5,469 | $64 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 40 | $2,941 | $29 |
| New patient visit (15+ min) | 35 | $2,887 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,505 | $64 |
| Advance care planning, first 30 minutes | 30 | $2,326 | $70 |
| Hospital observation care on day of discharge | 35 | $2,296 | $62 |
| Long return visit (40+ min) | 15 | $1,855 | $124 |
| Follow-up observation care per day, typically 35 minutes | 16 | $1,662 | $92 |
| Hospital discharge day management, 30 minutes or less | 16 | $1,115 | $66 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 24 | $1,095 | $35 |
2020: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 199 | $50,680 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 74 | $13,026 | $174 |
| Hospital discharge day management, more than 30 minutes | 97 | $9,829 | $98 |
| Initial hospital observation care per day, typically 70 minutes | 15 | $2,592 | $162 |
| Advance care planning, first 30 minutes | 31 | $2,448 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,508 | $66 |
| Hospital observation care on day of discharge | 22 | $1,271 | $58 |
| Follow-up observation care per day, typically 35 minutes | 12 | $1,131 | $87 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,130 | $63 |
2019: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 132 | $26,450 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $12,487 | $178 |
| Hospital discharge day management, more than 30 minutes | 41 | $4,180 | $97 |
| Hospital discharge day management, 30 minutes or less | 44 | $2,964 | $67 |
| Hospital observation care on day of discharge | 15 | $1,006 | $67 |
2018: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 156 | $34,577 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $14,360 | $175 |
| Hospital discharge day management, 30 minutes or less | 124 | $8,278 | $65 |
2017: 5 services
| Return visit (30+ min) | 73 | $9,498 | $96 |
| Short return visit (20+ min) | 77 | $6,842 | $64 |
| Transitional care management services for problem of high complexity | 16 | $4,401 | $220 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $1,801 | $139 |
| Long return visit (40+ min) | 12 | $1,551 | $129 |
2016: 3 services
| Return visit (30+ min) | 54 | $4,462 | $68 |
| Long return visit (40+ min) | 18 | $1,845 | $97 |
| Short return visit (20+ min) | 36 | $1,786 | $45 |
2014: 3 services
| Return visit (30+ min) | 60 | $13,799 | $88 |
| Short return visit (20+ min) | 30 | $2,534 | $51 |
| Long return visit (40+ min) | 11 | $1,779 | $119 |
2013: 6 services
| Return visit (30+ min) | 84 | $20,540 | $85 |
| Long return visit (40+ min) | 26 | $4,365 | $109 |
| Short return visit (20+ min) | 36 | $3,864 | $62 |
| New patient visit (45+ min) | 11 | $1,222 | $111 |
| Administration of influenza virus vaccine | 13 | $378 | $29 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 13 | $154 | $12 |
Medicaid work
$42,752 in 2023
Medicaid paid $42,752 for 1,217 billed services this clinician did in 2023, up to 145 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 388 | $19,600 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 191 | $7,021 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 201 | $6,683 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 154 | $3,713 |
| 1ST HOSP IP/OBS HIGH 75 | 26 | $2,225 |
| OFF/OP EST MAY X REQ PHY/QHP | 209 | $1,944 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 48 | $1,565 |
| 2023 | 1,217 | 7 | 145 | $42,752 |
| 2022 | 2,945 | 6 | 145 | $107,249 |
| 2021 | 777 | 7 | 85 | $26,408 |
| 2020 | 296 | 1 | 19 | $14,888 |
| 2019 | 29 | 1 | 14 | $948 |
See the largest Medicaid services in earlier years
2022
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 1,355 | $69,651 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 675 | $19,287 |
| SARSCOV CORONAVIRUS AG IA | 216 | $6,764 |
| OFF/OP EST MAY X REQ PHY/QHP | 490 | $4,667 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 104 | $4,033 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 105 | $2,848 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 345 | $12,644 |
| SARSCOV CORONAVIRUS AG IA | 128 | $4,189 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 129 | $3,828 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 97 | $3,700 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 14 | $826 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 13 | $657 |
| OFF/OP EST MAY X REQ PHY/QHP | 51 | $565 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 296 | $14,888 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 29 | $948 |
Drugs they prescribed that Part D paid
$23,859
Pharmacies billed $23,859 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
235 generic and fewer than 11 brand-name prescriptions · $23,859 in drug cost · 15 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 16 | $7,712 | $482 |
| Metoprolol | 13 | $103 | $8 |
| Isosorbide Mononitrate Er | 11 | $79 | $7 |
| Metoprolol | 12 | $55 | $5 |
| Atorvastatin | 13 | $53 | $4 |
See all 7 drugs
| Eliquis | 16 | $7,712 | $482 |
| Metoprolol | 13 | $103 | $8 |
| Isosorbide Mononitrate Er | 11 | $79 | $7 |
| Metoprolol | 12 | $55 | $5 |
| Atorvastatin | 13 | $53 | $4 |
| Furosemide | 18 | $45 | $3 |
| Spironolactone | 11 | $43 | $4 |
Year by year
| 2024 | 286 | 84 | None | None | $23,859 |
| 2023 | 514 | 118 | None | 12% | $42,959 |
| 2022 | 675 | 154 | 2% (12) | None | $67,600 |
| 2021 | 791 | 136 | None | None | $61,055 |
| 2020 | 432 | 119 | None | None | $40,550 |
| 2019 | 238 | 77 | None | 18% | $17,819 |
| 2018 | 404 | 169 | None | 13% | $24,574 |
| 2017 | 1,961 | 213 | None | None | $127,462 |
| 2016 | 738 | 164 | 2% (11) | None | $41,009 |
| 2015 | 353 | 58 | None | None | $12,520 |
| 2014 | 1,427 | 98 | 1% (15) | 18% | $62,348 |
| 2013 | 1,622 | 108 | 1% (19) | 24% | $77,093 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Eliquis | 18 | $10,779 | $599 |
| Symbicort | 12 | $5,070 | $422 |
| Hydralazine | 25 | $506 | $20 |
| Pantoprazole | 26 | $407 | $16 |
| Isosorbide Mononitrate Er | 23 | $342 | $15 |
| Atorvastatin | 18 | $338 | $19 |
| Metoprolol | 45 | $287 | $6 |
| Amiodarone | 14 | $217 | $16 |
| Metolazone | 11 | $215 | $20 |
| Famotidine | 21 | $173 | $8 |
| Amlodipine Besylate | 15 | $162 | $11 |
| Clopidogrel | 12 | $116 | $10 |
| Furosemide | 23 | $116 | $5 |
| Carvedilol | 13 | $65 | $5 |
2022: 15 drugs
| Eliquis | 44 | $25,261 | $574 |
| Xarelto | 16 | $9,027 | $564 |
| Pantoprazole | 60 | $767 | $13 |
| Hydralazine | 31 | $654 | $21 |
| Dicyclomine | 14 | $544 | $39 |
| Atorvastatin | 34 | $416 | $12 |
| Isosorbide Mononitrate Er | 21 | $284 | $14 |
| Potassium Chloride | 13 | $260 | $20 |
| Amlodipine Besylate | 20 | $241 | $12 |
| Gabapentin | 27 | $215 | $8 |
| Metoprolol | 35 | $184 | $5 |
| Furosemide | 37 | $160 | $4 |
| Lisinopril | 19 | $159 | $8 |
| Amoxicillin-Clavulanate Potass | 20 | $140 | $7 |
| Famotidine | 16 | $132 | $8 |
2021: 22 drugs
| Eliquis | 51 | $25,181 | $494 |
| Pantoprazole | 52 | $839 | $16 |
| Levetiracetam | 13 | $712 | $55 |
| Atorvastatin | 30 | $622 | $21 |
| Isosorbide Mononitrate Er | 28 | $399 | $14 |
| Famotidine | 18 | $275 | $15 |
| Hydralazine | 12 | $249 | $21 |
| Gabapentin | 17 | $246 | $14 |
| Pravastatin | 17 | $238 | $14 |
| Carvedilol | 13 | $196 | $15 |
| Amoxicillin-Clavulanate Potass | 11 | $160 | $15 |
| Metoprolol | 37 | $156 | $4 |
| Furosemide | 34 | $146 | $4 |
| Clopidogrel | 18 | $128 | $7 |
| Tamsulosin | 11 | $116 | $11 |
| Amlodipine Besylate | 21 | $106 | $5 |
| Donepezil | 12 | $95 | $8 |
| Ropinirole | 13 | $87 | $7 |
| Lisinopril | 26 | $69 | $3 |
| Montelukast | 13 | $55 | $4 |
| Atenolol | 12 | $52 | $4 |
| Prednisone | 14 | $42 | $3 |
2020: 12 drugs
| Eliquis | 22 | $12,707 | $578 |
| Amiodarone | 11 | $1,280 | $116 |
| Divalproex | 17 | $662 | $39 |
| Pantoprazole | 27 | $438 | $16 |
| Atorvastatin | 20 | $297 | $15 |
| Gabapentin | 19 | $239 | $13 |
| Isosorbide Mononitrate Er | 16 | $205 | $13 |
| Clopidogrel | 18 | $94 | $5 |
| Amlodipine Besylate | 19 | $82 | $4 |
| Furosemide | 20 | $74 | $4 |
| Carvedilol | 11 | $57 | $5 |
| Metoprolol | 15 | $56 | $4 |
2019: 4 drugs
| Eliquis | 18 | $8,055 | $447 |
| Gabapentin | 13 | $150 | $12 |
| Cephalexin | 13 | $111 | $9 |
| Furosemide | 11 | $56 | $5 |
2018: 9 drugs
| Amoxicillin-Clavulanate Potass | 14 | $246 | $18 |
| Atorvastatin | 14 | $236 | $17 |
| Lisinopril | 23 | $192 | $8 |
| Cephalexin | 26 | $188 | $7 |
| Levofloxacin | 12 | $158 | $13 |
| Pantoprazole | 11 | $140 | $13 |
| Prednisone | 23 | $96 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $67 | $6 |
| Furosemide | 12 | $47 | $4 |
2017: 46 drugs
| Memantine | 83 | $9,367 | $113 |
| Januvia | 14 | $7,550 | $539 |
| Eliquis | 14 | $6,226 | $445 |
| Advair Hfa | 13 | $4,727 | $364 |
| Advair Diskus | 11 | $4,538 | $413 |
| Linzess | 12 | $4,389 | $366 |
| Travatan Z | 19 | $3,944 | $208 |
| Risedronate | 30 | $3,784 | $126 |
| Atorvastatin | 162 | $2,745 | $17 |
| Flovent Hfa | 11 | $2,548 | $232 |
| Levothyroxine | 94 | $1,854 | $20 |
| Polyethylene Glycol 3350 | 17 | $890 | $52 |
| Tamsulosin | 36 | $880 | $24 |
| Ventolin Hfa | 14 | $813 | $58 |
| Pantoprazole | 40 | $762 | $19 |
| Amlodipine Besylate | 82 | $685 | $8 |
| Losartan | 56 | $656 | $12 |
| Fluticasone Propionate | 32 | $623 | $19 |
| Lisinopril | 74 | $588 | $8 |
| Mirtazapine | 12 | $559 | $47 |
| Furosemide | 68 | $454 | $7 |
| Donepezil | 26 | $436 | $17 |
| Metformin | 51 | $412 | $8 |
| Finasteride | 20 | $411 | $21 |
| Potassium Chloride | 22 | $403 | $18 |
| Diltiazem 24hr Er | 20 | $371 | $19 |
| Metoprolol | 40 | $349 | $9 |
| Gabapentin | 39 | $328 | $8 |
| Megestrol Acetate | 15 | $327 | $22 |
| Omeprazole | 22 | $313 | $14 |
| Simvastatin | 24 | $299 | $12 |
| Montelukast | 11 | $288 | $26 |
| Sertraline | 40 | $283 | $7 |
| Isosorbide Mononitrate Er | 13 | $277 | $21 |
| Klor-Con Sprinkle | 11 | $226 | $21 |
| Alendronate | 17 | $206 | $12 |
| Levetiracetam | 16 | $194 | $12 |
| Atenolol | 31 | $186 | $6 |
| Trazodone | 22 | $183 | $8 |
| Prednisone | 27 | $180 | $7 |
| Hydrochlorothiazide | 34 | $150 | $4 |
| Glipizide | 17 | $129 | $8 |
| Carvedilol | 14 | $107 | $8 |
| Famotidine | 14 | $73 | $5 |
| Citalopram Hbr | 13 | $66 | $5 |
| Hydralazine | 12 | $62 | $5 |
2016: 17 drugs
| Memantine | 13 | $1,374 | $106 |
| Atorvastatin | 45 | $697 | $15 |
| Polyethylene Glycol 3350 | 13 | $398 | $31 |
| Levothyroxine | 19 | $385 | $20 |
| Tamsulosin | 20 | $299 | $15 |
| Losartan | 23 | $297 | $13 |
| Lisinopril | 27 | $231 | $9 |
| Potassium Chloride | 11 | $215 | $20 |
| Fluticasone Propionate | 14 | $205 | $15 |
| Amlodipine Besylate | 16 | $189 | $12 |
| Furosemide | 26 | $156 | $6 |
| Simvastatin | 15 | $155 | $10 |
| Metformin | 21 | $150 | $7 |
| Sertraline | 21 | $148 | $7 |
| Metoprolol | 15 | $86 | $6 |
| Trazodone | 13 | $82 | $6 |
| Prednisone | 11 | $41 | $4 |
2015: 10 drugs
| Levothyroxine | 27 | $678 | $25 |
| Atorvastatin | 17 | $262 | $15 |
| Metoprolol | 13 | $258 | $20 |
| Simvastatin | 17 | $109 | $6 |
| Losartan | 13 | $93 | $7 |
| Lisinopril | 12 | $86 | $7 |
| Sertraline | 18 | $80 | $4 |
| Atenolol | 11 | $67 | $6 |
| Metformin | 14 | $44 | $3 |
| Amlodipine Besylate | 12 | $18 | $2 |
2014: 45 drugs
| Diovan | 32 | $7,816 | $244 |
| Benicar | 12 | $2,861 | $238 |
| Crestor | 12 | $2,532 | $211 |
| Levothyroxine | 74 | $1,717 | $23 |
| Micardis Hct | 11 | $1,615 | $147 |
| Atorvastatin | 70 | $1,472 | $21 |
| Lansoprazole | 12 | $1,351 | $113 |
| Pramipexole Dihydrochloride | 28 | $1,064 | $38 |
| Diltiazem 24hr Er | 12 | $727 | $61 |
| Synthroid | 29 | $604 | $21 |
| Losartan | 31 | $517 | $17 |
| Phenobarbital | 13 | $474 | $36 |
| Simvastatin | 52 | $435 | $8 |
| Fluticasone Propionate | 20 | $410 | $20 |
| Diclofenac | 23 | $408 | $18 |
| Clopidogrel | 20 | $383 | $19 |
| Omeprazole | 34 | $380 | $11 |
| Metformin | 47 | $309 | $7 |
| Polyethylene Glycol 3350 | 11 | $277 | $25 |
| Zolpidem | 40 | $265 | $7 |
| Lisinopril | 44 | $254 | $6 |
| Enalapril Maleate | 12 | $251 | $21 |
| Potassium Chloride | 15 | $235 | $16 |
| Olanzapine | 13 | $231 | $18 |
| Amlodipine Besylate | 30 | $216 | $7 |
| Lovastatin | 11 | $215 | $20 |
| Trazodone | 31 | $202 | $7 |
| Torsemide | 15 | $201 | $13 |
| Proctosol-Hc | 11 | $199 | $18 |
| Atenolol | 38 | $199 | $5 |
| Bupropion Hcl Sr | 15 | $192 | $13 |
| Triamterene-Hydrochlorothiazid | 12 | $180 | $15 |
| Sertraline | 28 | $176 | $6 |
| Escitalopram | 15 | $166 | $11 |
| Finasteride | 16 | $166 | $10 |
| Oxybutynin Chloride | 11 | $164 | $15 |
| Atenolol-Chlorthalidone | 11 | $157 | $14 |
| Gabapentin | 16 | $149 | $9 |
| Pantoprazole | 14 | $145 | $10 |
| Citalopram Hbr | 16 | $122 | $8 |
| Hydrochlorothiazide | 29 | $110 | $4 |
| Alprazolam | 16 | $53 | $3 |
| Carvedilol | 11 | $52 | $5 |
| Furosemide | 13 | $49 | $4 |
| Diazepam | 14 | $30 | $2 |
2013: 49 drugs
| Diovan | 42 | $8,535 | $203 |
| Actonel | 22 | $3,767 | $171 |
| Crestor | 14 | $3,260 | $233 |
| Premarin | 18 | $2,239 | $124 |
| Benicar | 11 | $2,166 | $197 |
| Estrace | 15 | $1,981 | $132 |
| Atorvastatin | 68 | $1,723 | $25 |
| Micardis Hct | 12 | $1,606 | $134 |
| Vagifem | 13 | $1,204 | $93 |
| Diltiazem 24hr Er | 19 | $1,161 | $61 |
| Clopidogrel | 17 | $1,099 | $65 |
| Prempro | 11 | $1,067 | $97 |
| Levothyroxine | 82 | $957 | $12 |
| Omeprazole | 36 | $675 | $19 |
| Synthroid | 23 | $530 | $23 |
| Simvastatin | 55 | $477 | $9 |
| Diclofenac | 22 | $467 | $21 |
| Pramipexole Dihydrochloride | 20 | $464 | $23 |
| Losartan | 31 | $449 | $14 |
| Sertraline | 44 | $443 | $10 |
| Acyclovir | 13 | $442 | $34 |
| Lisinopril | 50 | $426 | $9 |
| Fluticasone Propionate | 20 | $404 | $20 |
| Potassium Chloride | 16 | $372 | $23 |
| Polyethylene Glycol 3350 | 13 | $370 | $28 |
| Metformin | 36 | $330 | $9 |
| Clotrimazole-Betamethasone | 12 | $328 | $27 |
| Phenobarbital | 11 | $325 | $30 |
| Hydrochlorothiazide | 30 | $324 | $11 |
| Oxybutynin Chloride | 24 | $218 | $9 |
| Pravastatin | 14 | $217 | $15 |
| Pantoprazole | 14 | $208 | $15 |
| Liothyronine | 11 | $203 | $18 |
| Zolpidem | 37 | $202 | $5 |
| Amlodipine Besylate | 26 | $198 | $8 |
| Olanzapine | 11 | $192 | $17 |
| Tamsulosin | 11 | $176 | $16 |
| Alendronate | 11 | $174 | $16 |
| Hydrocodone-Acetaminophen | 15 | $171 | $11 |
| Atenolol | 33 | $160 | $5 |
| Hydralazine | 11 | $148 | $13 |
| Citalopram Hbr | 18 | $143 | $8 |
| Trazodone | 21 | $129 | $6 |
| Carvedilol | 11 | $117 | $11 |
| Gabapentin | 17 | $112 | $7 |
| Furosemide | 24 | $91 | $4 |
| Prednisone | 14 | $43 | $3 |
| Alprazolam | 13 | $39 | $3 |
| Diazepam | 16 | $39 | $2 |
Money from drug and device companies
$150 in 2023
| 2023 | 3 | 6 | None | $150 |
| 2022 | 3 | 8 | None | $159 |
| 2021 | 4 | 18 | None | $442 |
| 2020 | 7 | 26 | None | $456 |
| 2019 | 4 | 6 | None | $202 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Eliquis | $85 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $44 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $21 | 1 payment
|
See all 6 published payments
| Pfizer | Meals · 2023-08-19 | Eliquis | $29 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2023-07-14 | Lifevest | $22 |
| Pfizer | Meals · 2023-07-12 | Eliquis | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2023-04-21 | Eliquis | $21 |
| Pfizer | Meals · 2023-04-20 | Eliquis | $26 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2023-04-12 | Lifevest | $22 |
See earlier years (2022, 2021, 2020, 2019)
2022: $159
| Janssen Pharmaceuticals | Xarelto | $109 | 6 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $30 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $20 | 1 payment
|
2021: $442
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $148 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $135 | 7 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $86 | 4 payments
|
| Pfizer | Eliquis | $74 | 3 payments
|
2020: $456
| Janssen Pharmaceuticals | Xarelto | $235 | 15 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $107 | 5 payments
|
| Pfizer | Eliquis | $42 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $23 | 1 payment
|
| iRhythm Technologies | Zio Patch | $22 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $14 | 1 payment
|
| Novo Nordisk | Ozempic | $14 | 1 payment
|
2019: $202
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $137 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $40 | 2 payments
|
| Pfizer | Eliquis | $14 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $11 | 1 payment
|
Professional record
- NPI
- 1346273406
- Licence
- CA A53933California A53933: Current · expires 2026-10-31
- Trained
- Texas Tech University Health Science Center School of Medicine, 1993 · 33 years ago
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-07-09
- NPI last updated
- 2024-04-18
- NPI record certified
- 2024-04-18
This is when the NPI record was last certified, not a medical board exam.